AGO Breast Study Group

Peter Fasching is tweeting

[AGO Breast Study Group @AgoStudy]

MonarchE reported an overall survival benefit of abemaciclib in high risk early breast cancer. https://t.co/QF39JlUigy

Likely we see that data at this years ESMO in Berlin https://t.co/CHKKUKKSZ5 Good chance we also see an update of NATALEE. Great that these studies mature.

[AGO Breast Study Group @AgoStudy]

Mal eine andere Art der Publikation: Mammografie-Screening senkt Mortalität wahrscheinlich um 20 bis 30% (bei allen Schwierigkeiten solcher Auswertungen). Toller Erfolg für die Prävention. Prävention muss weiter besser werden!!!

https://t.co/ClP0bOS4jG

https://t.co/JQ9sxY4E0R

[AGO Breast Study Group @AgoStudy]

Now Destiny-B06 Study with a positive CHMP opinion

https://t.co/x25ZcdGzhH

Then T-Dxd will possible in ultralow HER2 expressing tumors and without previous chemotherapy. Good to have more therapeutic options for new therapy sequences.

#breastcancer #tdxd #ultralow

[AGO Breast Study Group @AgoStudy]

Serena-6 study seems to be positive - another milestone in individualized healthcare for patients with advanced breast cancer

https://t.co/NJJdkkSyHL

Hopefully we see this data at ASCO2025

#breastcancer #serd #asco2025

[AGO Breast Study Group @AgoStudy]

Neoadjvuant Radiotherapy: new insights with important information that might be useful current clinical trial design
https://t.co/9LEUvqmGWE

#breastcancer #radiotherapy

[AGO Breast Study Group @AgoStudy]

Great month for Datopotamab-deruxtecan for HRpos/HER2neg aBC patients: After Approval in the US two weeks ago:
https://t.co/qJT65Q2jhq

Also Approval recommendation by the EMA yesterday
https://t.co/HuPpKnebvV

[AGO Breast Study Group @AgoStudy]

INAVO120 Study seems to be positive for overall survival. Excellent news for patients !!!
https://t.co/W1t7T9urwY
Assuming data will be presented at ASCO in 4 months we have to wait for this data quite some time. Maybe find a way to immendiately share the data, when anndouncing?

[AGO Breast Study Group @AgoStudy]

Good for the therapy landscape: T-Dxd approved in the U.S. in the DB-06 Population (Patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies).

https://t.co/GKLA9xYCsP

https://t.co/EPXfX2mR6S

[AGO Breast Study Group @AgoStudy]

Gipfelstürmer Neuauflage 2025 in der "wahren Hauptstadt Deutschlands" (Zitat eines berühmten Gynäkologen): https://t.co/utP9h3uOeC

[onkowissen @onkowissen]

Nächste Woche geht es wieder los! Der #SABCS24 öffnet seine Türen! #onkowissenTV ist natürlich wieder live vor Ort und berichtet von den neuesten Daten! Ganz neu dieses Jahr: der onkowissenTV Livestream mit allen wichtigen Updates des Jahres 2024 im Bereich #Mammakarzinom. Jetzt Platz sichern und nicht verpassen, am 14.12. um 14:30 MEZ: https://t.co/WlQmBFjVAM

@DLueftner @Mbpzp2 @HartkopfAndreas @hckol @volkmar_mueller @juliaradosa @SABCSSanAntonio

[AGO Breast Study Group @AgoStudy]

Kisqali - opinion on variation to marketing authorisation | EMA https://t.co/AgIo1zFth4

After the U.S., now positive opinion on early breast cancer ribociclib use a consequence of positive outcome data of NATALEE https://t.co/1g5HJN1S2e

#breastcancer #ribociclib #natalee

[AGO Breast Study Group @AgoStudy]

Keynote-522 every third breast cancer death prevented.

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine https://t.co/jXXbyYwbEl

[AGO Breast Study Group @AgoStudy]

Yesterday 4yr survival update of NATALEE: https://t.co/kwZpnfEL74

Today FDA Approval for Ribociclib in the adjuvant setting: https://t.co/R5YOzTjtMZ

#breastcancer

[AGO Breast Study Group @AgoStudy]

Gestern 4yr survival update von NATALEE: https://t.co/kwZpnfEL74

Heute in den USA die Zulassung für high risk HRpos/HER2neg eBC: https://t.co/R5YOzTjtMZ

#brustkrebs #breastcancer

[AGO Breast Study Group @AgoStudy]

Breast Cancer Screening Interval: Screening Ergebnisse anders herum. Screening scheint auch bei jungen Frauen das Stadium günstig zu beeinflussen. Zeit, auch das Vorgehen in Deutschland neu zu disktuieren? https://t.co/3ieOcfr0NP

[AGO Breast Study Group @AgoStudy]

Die finalen Mammografie-Screening-Empfehlungen, die das Eintritts-Alter in den USA auf 40 senken, sind verabschiedet

https://t.co/RRRQk9tQzx

Zeit, sich auch in Deutschland die Epidemiologie und das Erkrankungsalter noch einmal anzuschauen?
#mammakarzinom #screening #mammografie

[AGO Breast Study Group @AgoStudy]

Jetzt anmelden: AGO Mammakarzinom State of the Art 2024 – alle neuen Therapie-Empfehlungen der Kommission Mamma live in Frankfurt am 02.03.2024. Auch virtuelle Teilnahme möglich.
https://t.co/w6HM8aCpIY

[AGO Breast Study Group @AgoStudy]

New analysis in HRPos/HER2neg BC patients shows the prognosis of the groups according to inclusion/exclusion criteria of MonarchE and NATALEE in a German Cohort study of letrozole treated HRpos/HER2neg patients. https://t.co/hoLYBtJGIv

[AGO Breast Study Group @AgoStudy]

Virtuell und vor Ort: neue Therapie-Empfehlungen für Patientinnen mit Mammakarzinom und für Früherkennung/Diagnostik
#mammakarzinom #brustkrebs #therapie #diagnostik

https://t.co/w6HM8aCXyw

[AGO Breast Study Group @AgoStudy]

The German RIBECCA Study was a phase IIIB study short after the publication of Monaleesa-2. With 21.8 months median PFS is very similar compared to the randomized clinical trials. Large translational research program to follow.

https://t.co/C2HV385dtA